24 May 2013
Keywords: lexicon, initiates, ph, ii, ibs, trial, lx1031
Article | 19 January 2009
The USA's Lexicon Pharmaceuticals has initiated a Phase II trial of LX1031, its oral drug candidate for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 January 2009
23 May 2013
© 2013 thepharmaletter.com